Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity

9 november 2026 bijgewerkt door: Dr. August Wolff GmbH & Co. KG Arzneimittel

Double-blind, Randomized, Non-inferiority Clinical Study to Evaluate the Efficacy of a Toothpaste Containing 20% Hydroxyapatite (HAP) and 2% Calcium Hypophosphite (CaP) Compared With Two Comparator Toothpastes by Assessing the Impact on Symptoms of Dentin Hypersensitivity Over a Study Duration of 56 Days (8 Weeks), as Well as Its Safety and Tolerability in Research Participants With Dentin Hypersensitivity

This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.

A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.

The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.

Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.

Studie Overzicht

Gedetailleerde beschrijving

Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.

Studietype

Ingrijpend

Inschrijving (Geschat)

186

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Valinhos
      • São Paulo, Valinhos, Brazilië, 13270-180
        • Werving
        • Kosmoscience

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Men and women aged between 18 and 65 years.
  • Presenting with dentin hypersensitivity.
  • At least one eligible tooth (incisor, canine, premolar, or first molar) must have visibly exposed cervical dentin on the facial surface and a score at least 30 mm on the 100-mm VAS immediately after the airblast test (VAS: 0 mm: no sensitivity; 100 mm: worst imaginable sensitivity)
  • Proper periodontal health (i.e. no probing depth > 4 mm, or other conditions that might explain their apparent dentin hypersensitivity
  • To be in good general health, as assessed by the investigator.

Exclusion Criteria:

  • Previous professional desensitizing treatment within the past 3 months (e.g., in-office fluoride varnish, laser desensitization)
  • Use of over-the-counter desensitizing products within the previous 8 weeks
  • Medical histories made remarkable by chronic use of antibiotics, anti-inflammatory, analgesic, anticonvulsant, sedative, and psychotropic drugs; or ongoing active treatment with any of these drug classes at the time of screening
  • Pregnancy and breastfeeding
  • Allergies and idiosyncratic responses to product ingredients (e.g., any ingredient of the investigational or comparator products)
  • Teeth or periodontium with pathology or defects likely to cause pain (e.g., periodontal abscess, tooth mobility greater than Grade 1) (applies to teeth designated for sensitivity assessment)

Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: 20% Hydroxyapatite and 2% Calcium Hypophosphite Toothpaste

Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Actieve vergelijker: Stannous Fluoride Toothpaste

Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Actieve vergelijker: 8% Arginine Toothpaste

Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56
Tijdsspanne: Baseline (Day 1) to Day 56 (±3 Days)

The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm).

Baseline (Day 1) to Day 56 (±3 Days)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean change in VAS (Cold Water Test) from Baseline to Day 56
Tijdsspanne: Baseline (Day 1) to Day 56 (±3 Days)

Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 56 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 28
Tijdsspanne: Baseline (Day 1) to Day 28 (±3 Days)

Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application
Tijdsspanne: Day 1 (Baseline and directly after the first application)

Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Day 1 (Baseline and directly after the first application)
Mean change in VAS (Cold Water test) from Baseline to Day 28
Tijdsspanne: Baseline (Day 1) to Day 28 (±3 Days)

Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Baseline (Day 1) to Day 28 (±3 Days)
Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application
Tijdsspanne: Day 1 (Baseline and directly after the first application)

Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity).

Day 1 (Baseline and directly after the first application)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Ana Lúcia Tabarini Alves Pinheiro, MD, Kosmoscience Ciência e Tecnologia Cosmética, Importação e Exportação Ltda.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 november 2026

Primaire voltooiing (Geschat)

1 januari 2027

Studie voltooiing (Geschat)

1 februari 2027

Studieregistratiedata

Eerst ingediend

9 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

9 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

All data and information retrieved within the investigation are an intellectual property of the Sponsor.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren